Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial.
Lavole A, Greillier L, Mazières J, Monnet I, Kiakouama-Maleka L, Quantin X, Spano JP, Lena H, Fraisse P, Janicot H, Audigier-Valette C, Langlais A, Morin F, Makinson A, Cadranel J; French Cooperative Thoracic Intergroup (IFCT). Lavole A, et al. Among authors: greillier l. Eur Respir J. 2020 Aug 27;56(2):1902066. doi: 10.1183/13993003.02066-2019. Print 2020 Aug. Eur Respir J. 2020. PMID: 32444410 Free article. Clinical Trial.
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
Demerlé C, Gorvel L, Mello M, Pastor S, Degos C, Zarubica A, Angelis F, Fiore F, Nunes JA, Malissen B, Greillier L, Guittard G, Luche H, Barlesi F, Olive D. Demerlé C, et al. Among authors: greillier l. J Immunother Cancer. 2023 May;11(5):e006348. doi: 10.1136/jitc-2022-006348. J Immunother Cancer. 2023. PMID: 37230538 Free PMC article.
[Prognostic indicators in stage I non-small cell lung cancer].
Barlési F, Doddoli C, Greillier L, Astoul P, Giudicelli R, Fuentes P, Thomas P. Barlési F, et al. Among authors: greillier l. Rev Mal Respir. 2004 Feb;21(1):93-103. doi: 10.1016/s0761-8425(04)71239-5. Rev Mal Respir. 2004. PMID: 15260042 Review. French.
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study).
LeCaer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, Vergnenegre A, Dujon C, Delhoume JY, Chouaid C; GFPC 0504 Team. LeCaer H, et al. Br J Cancer. 2011 Oct 11;105(8):1123-30. doi: 10.1038/bjc.2011.331. Epub 2011 Sep 20. Br J Cancer. 2011. PMID: 21934690 Free PMC article. Clinical Trial.
186 results